Please assess the completion status of the following clinical trial:

Trial Title: Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with RRMS or SPMS with new contrast-enhancing lesions who will start as part of their standard of care ACTH.~Exclusion Criteria:~* Patients having received oral or IV corticosteroids within one month prior to initial scan demonstrating contrast enhancing lesion~* Patients with known or new allergy to ACTH~* Patients being treated with Natalizumab, Rituximab, and Cyclophosphamide~* Patients unwilling to have serial MRI exams~* Patients unable to undergo MRI imaging because of having an artificial heart valve, metal plate, pin, or other metallic objects in their body or is unable to complete all the MRI scans required for this study~* Patients with acute or chronic renal disease in whom administration of gadolinium may pose risk of nephrogenic systemic fibrosis~* Patients that are pregnant~* Premenopausal woman not willing to use at least one form of contraception~* Patients with a known history of diabetes mellitus~* Patients with a known history of osteoporosis or bone density values in the osteoporosis range at screening~* Progressive neurological disorder other than RRMS or SPMS~* Clinically significant cardiovascular disease, including myocardial infarct within last 6 months, unstable ischemic heart disease, congestive heart failure, or angina~* Subjects on chronic steroid therapy for treatment of MS or other systematic disease~* Subject currently has a significant medical condition (other than MS) including the following: neurological, psychiatric, metabolic, hepatic, renal, hematological, pulmonary, cardiovascular (including uncontrolled hypertension), gastrointestinal, urological disorder, or central nervous system (CNS) infection that would pose a risk to the subject if they were to participate in the study or that might confound the results of the study~  o Note: Active medical conditions that are minor or well-controlled are not exclusionary if, in the judgment of the Primary Investigator, they do not affect risk or the subject or the study results.~* Subject is unable to cooperate with any study procedures, unlikely to adhere to the study procedures and keep appointments, in the opinion of the Investigator, or was planning to relocate during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- One Time Treatment (Type: ACTIVE_COMPARATOR): MS patients enrolled in this study will be randomized into:~Intervention for Group A: 80 units/day ACTH (H.P. Acthar®)for 3-5 days (The dose could be adjusted based on the individual needs of the patients up to 80-120 units daily for 2-3 weeks.)
- Monthly Treatments (Type: EXPERIMENTAL): Intervention for Group B: 80 units/day ACTH (H.P. Acthar®) for 3-5 days (The dose could be adjusted based on the individual needs of the patients up to 80-120 units daily for 2-3 weeks.), followed by monthly 80 units/day ACTH for 3 days for 12 months of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues